(Q34079586)

30 July 2017

1 reference

title

Treatment of Alzheimer's disease: rationale and strategies (English)

1 reference

30 July 2017

0 references

Grundman M

1

1 reference

30 July 2017

Thal LJ

series ordinal

2

1 reference

30 July 2017

publication date

1 November 2000

1 reference

30 July 2017

1 reference

30 July 2017

volume

18

1 reference

30 July 2017

issue

4

1 reference

30 July 2017

page(s)

807-828

1 reference

Inflammatory mechanisms in Alzheimer's disease: implications for therapy

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease?: The Rotterdam Study

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Improved learning and memory in aged rats with chronic administration of the nicotinic receptor agonist GTS-21.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Neuronal loss in different parts of the nucleus basalis is related to neuritic plaque formation in cortical target areas in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Potential treatment of Alzheimer disease using cholinergic channel activators (ChCAs) with cognitive enhancement, anxiolytic-like, and cytoprotective properties.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer's disease: results of a placebo-controlled, double-blind, pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Interleukin-6 and α-2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

The influence of estrous cycle and intrastriatal estradiol on sensorimotor performance in the female rat

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Protective action of idebenone against excitotoxic degeneration in cultured cortical neurons

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

The effects of donepezil in Alzheimer's disease - results from a multinational trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

The Canadian Study of Health and Aging: risk factors for Alzheimer's disease in Canada

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Metrifonate treatment of the cognitive deficits of Alzheimer's disease. Metrifonate Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Cholinergic strategies in the treatment of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Selective loss of central cholinergic neurons in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Enhancement of memory processes in Alzheimer's disease with multiple-dose intravenous physostigmine.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Suppression of A beta-induced monocyte neurotoxicity by antiinflammatory compounds.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Immunoglobulins and complement factors in senile plaques. An immunoperoxidase study.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Clinical effects of choline in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Nucleus basalis neuronal loss, neuritic plaques and choline acetyltransferase activity in advanced Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Observations in a preliminary open trial of estradiol therapy for senile dementia-Alzheimer's type.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

The cholinergic hypothesis of Alzheimer's disease: a review of progress

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

L-deprenyl in Alzheimer's disease: cognitive and behavioral effects

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Morphological response of axotomized septal neurons to nerve growth factor

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Cognitive impairment and mortality in a cohort of elderly people

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

1 reference

7 January 2021

Phagocytic microglia release cytokines and cytotoxins that regulate the survival of astrocytes and neurons in culture

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Effect of AIT-082, a purine analog, on working memory in normal and aged mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Gonadal steroids regulate dendritic spine density in hippocampal pyramidal cells in adulthood

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Safety of tacrine: clinical trials, treatment IND, and postmarketing experience

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Vitamin E and Alzheimer disease: the basis for additional clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Low body weight in Alzheimer's disease is associated with mesial temporal cortex atrophy.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Demonstration of microglial cells in and around senile (neuritic) plaques in the Alzheimer brain. An immunohistochemical study using a novel monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Estrogen replacement therapy in older women. Comparisons between Alzheimer's disease cases and nondemented control subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

In vivo effects by estrone sulfate on the central nervous system-senile dementia (Alzheimer's type).

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Estrogen as a growth factor to central nervous cells. Estrogen treatment promotes development of acetylcholinesterase-positive basal forebrain neurons transplanted in the anterior eye chamber

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Identification of a Novel Aspartic Protease (Asp 2) as β-Secretase

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

A 25-week placebo-controlled study of eptastigmine in patients with Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Efficacy and safety of eptastigmine for the treatment of patients with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Two-year treatment of Alzheimer's disease with eptastigmine. The Eptastigmine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Complements, microglial cells and amyloid fibril formation

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Initiation and propagation stages of beta-amyloid are associated with distinctive apolipoprotein E, age, and gender profiles

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

The prevalence of dementia: a quantitative integration of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Reduction of motor behavioural deficits in senescence via chronic prolactin or estrogen administration: time course and putative mechanisms of action

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore Longitudinal Study of Aging

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Nutritional status and cognitive functioning in a normally aging sample: a 6-y reassessment.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Nicotinic acetylcholine involvement in cognitive function in animals

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Estradiol increases choline acetyltransferase activity in specific basal forebrain nuclei and projection areas of female rats

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Amyloid-associated proteins α1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Association of Ginkgo biloba with intracerebral hemorrhage

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Hormone replacement therapy and other potential treatments for dementias

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Effects of estrogen treatment on sensorimotor task performance and brain dopamine concentrations in gonadectomized male and female CD-1 mice

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Estradiol and progesterone regulate neuronal structure and synaptic connectivity in adult as well as developing brain

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Activation of the classical complement pathway in brain tissue of Alzheimer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Anti‐inflammatory agents as a therapeutic approach to Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

AIT-082, a unique purine derivative, enhances nerve growth factor mediated neurite outgrowth from PC12 cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Reappraising neurotransmitter-based strategies

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

The Clinical Dementia Rating (CDR): current version and scoring rules

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Nicotinic system involvement in Alzheimer's and Parkinson's diseases. Implications for therapeutics.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Intravenous nicotine in Alzheimer's disease: a pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Evaluation of estrogen treatment in female patients with dementia of the Alzheimer type

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Does Alzheimer's disease start early in life?

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Estrogen deficiency and risk of Alzheimer's disease in women.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Estrogen replacement therapy and risk of Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Increased regional cerebral glucose metabolism and semantic memory performance in Alzheimer's disease: a pilot double blind transdermal nicotine positron emission tomography study

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

The relation between antioxidants and memory performance in the old and very old.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Effects of physostigmine and lecithin on memory in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Mild cognitive impairment: clinical characterization and outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: studies of ERalpha and ERbeta expressed in Chinese hamster ovary cells

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Nonsteroidal anti-inflammatory drugs in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Clinical trial of indomethacin in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

A new rating scale for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Spontaneous hyphema associated with ingestion of Ginkgo biloba extract

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Aricept-induced nightmares in Alzheimer's disease: 2 case reports.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Nicotinic Stimulation of [3H]Acetylcholine Release from Mouse Cerebral Cortical Synaptosomes

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Spontaneous bilateral subdural hematomas associated with chronic Ginkgo biloba ingestion

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Estradiol in the striatum: effects on behavior and dopamine receptors but no evidence for membrane steroid receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Estrogen and/or androgen replacement therapy and cognitive functioning in surgically menopausal women.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Role of estrogen replacement therapy in memory enhancement and the prevention of neuronal loss associated with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Purification and cloning of amyloid precursor protein beta-secretase from human brain

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Age-associated neuronal atrophy occurs in the primate brain and is reversible by growth factor gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Antibody clears senile plaques

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Risk of Alzheimer's disease and duration of NSAID use.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Cholinomimetic treatment of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

A 24-week randomized trial of controlled-release physostigmine in patients with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Oral physostigmine and lecithin improve memory in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Choline chloride fails to improve cognition in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Estrogen receptors colocalize with low-affinity nerve growth factor receptors in cholinergic neurons of the basal forebrain

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Is amyloidogenesis during Alzheimer's disease due to an IL-1-/IL-6-mediated 'acute phase response' in the brain?

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

4-[[2-(1-Methyl-2-pyrrolidinyl)ethyl]thio]phenol hydrochloride (SIB-1553A): a novel cognitive enhancer with selectivity for neuronal nicotinic acetylcholine receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

The association of weight change in Alzheimer's disease with severity of disease and mortality: a longitudinal analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Nicotinic acetylcholine binding sites in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Idebenone protects hepatic microsomes against oxygen radical-mediated damage in organ preservation solutions

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970227-9

7 January 2021

10.1016/S0733-8619(05)70227-9

Identifiers

DOI

1 reference

30 July 2017

1 reference